Search

Your search keyword '"Merghoub, Taha"' showing total 1,089 results

Search Constraints

Start Over You searched for: Author "Merghoub, Taha" Remove constraint Author: "Merghoub, Taha"
1,089 results on '"Merghoub, Taha"'

Search Results

3. Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models

5. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

7. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

8. Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer

9. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma

10. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

11. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade

12. TAD hierarchy restricts poised LTR activation and loss of TAD hierarchy promotes LTR co-option in cancer

13. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer

14. Fundamental immune–oncogenicity trade-offs define driver mutation fitness

16. Anatomic position determines oncogenic specificity in melanoma

17. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

19. In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response

22. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways

24. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

25. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity

26. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

27. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways

28. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours

29. Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model.

30. Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib

31. 878 T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants

36. In vivo optical imaging-guided targeted sampling for precise diagnosis and molecular pathology

37. Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade

38. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

39. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity

40. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

44. Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness

45. Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

46. Enabling continuous immune cell recirculation on a microfluidic array to study immunotherapeutic interactions in a recapitulated tumour microenvironment.

47. Supplementary Table S5 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

48. Supplementary Methods S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

49. Supplementary Figure S10 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

50. Data from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Catalog

Books, media, physical & digital resources